Bone Marrow Cells in Myeloma and Drug Resistance
Author Information
Author(s): Stephanie Markovina, Natalie S Callander, Shelby L O'Connor, Guangwu Xu, Yufang Shi, Catherine P Leith, KyungMann Kim, Parul Trivedi, Jaehyup Kim, Peiman Hematti, Shigeki Miyamoto
Primary Institution: University of Wisconsin School of Medicine and Public Health
Hypothesis
BMSCs from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells.
Conclusion
BMSCs from MM patients enhance NF-κB activity in MM cells through secreted factors, contributing to drug resistance.
Supporting Evidence
- BMSCs from MM patients significantly enhance NF-κB activity in MM cells compared to non-MM BMSCs.
- IL-8 was secreted at higher levels by MM BMSCs and contributed to NF-κB activation.
- Co-culture with MM BMSCs resulted in a statistically significant increase in NF-κB activity in MM cells.
Takeaway
The study found that certain cells from the bone marrow of myeloma patients help cancer cells resist treatment by making them stronger.
Methodology
The study involved co-culturing BMSCs from MM patients and normal donors with MM cell lines to assess NF-κB activity.
Limitations
The study's findings may not be generalizable due to the limited number of patients and the complexity of interactions in the tumor microenvironment.
Participant Demographics
BMSCs were derived from 25 patients with diagnosed MM and 21 normal donors.
Statistical Information
P-Value
0.001
Statistical Significance
p = 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website